| Mrs Tracey L Johnson, LISW-CP | |
|
150 Oakland Ave, Rock Hill, SC 29730-4073 | |
| (803) 334-4056 | |
| Not Available |
| Full Name | Mrs Tracey L Johnson |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 26 Years |
| Location | 150 Oakland Ave, Rock Hill, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396816385 | NPI | - | NPPES |
| CJ5560 | Other | SC | RAILROAD MEDICARE |
| 570629234006 | Other | SC | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 6970 (South Carolina) | Primary |
| Entity Name | Stepping Stones Counesling Services,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124344486 PECOS PAC ID: 1557556198 Enrollment ID: O20101109001174 |
News Archive
Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).
According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020.
Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders. The study is funded by a $9 million grant from the National Institutes of Health (NIH) as part of a nationwide initiative to examine how genetic variations cause heart, lung and blood diseases.
BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.
› Verified 1 days ago
| Entity Name | Tl Johnson Counseling Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467235143 PECOS PAC ID: 8022462613 Enrollment ID: O20231002000213 |
News Archive
Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).
According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020.
Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders. The study is funded by a $9 million grant from the National Institutes of Health (NIH) as part of a nationwide initiative to examine how genetic variations cause heart, lung and blood diseases.
BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Tracey L Johnson, LISW-CP Po Box 36144, Rock Hill, SC 29732-0502 Ph: (803) 334-4056 | Mrs Tracey L Johnson, LISW-CP 150 Oakland Ave, Rock Hill, SC 29730-4073 Ph: (803) 334-4056 |
News Archive
Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).
According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020.
Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders. The study is funded by a $9 million grant from the National Institutes of Health (NIH) as part of a nationwide initiative to examine how genetic variations cause heart, lung and blood diseases.
BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.
› Verified 1 days ago
Mrs. Julia B Friar, LCSWA Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3206 Newcastle Dr, Rock Hill, SC 29732 Phone: 803-280-5504 | |
Takima Nelson, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 448 Lakeshore Pkwy Ste 200, Rock Hill, SC 29730 Phone: 803-328-3177 | |
Miss Naomi Otano, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 205 Piedmont Blvd Ste 100, Rock Hill, SC 29732 Phone: 803-327-2012 | |
Miss Beatrice Alisha Frazier, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1070 Heckle Blvd, Rock Hill, SC 29732 Phone: 803-909-7500 Fax: 803-909-7440 | |
Ms. Ariel Gagne, LISW-CP Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 289 Greentree St, Rock Hill, SC 29730 Phone: 864-542-6185 | |
Debra Nicole Riley, LISW-CP Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 291 Willowbrook Ave Ste 102, Rock Hill, SC 29730 Phone: 803-347-7828 | |
Mary Angela Aldrich, LISW-CP, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 454 S. Anderson Road, Suite 211, Rock Hill, SC 29730 Phone: 803-324-9808 Fax: 803-324-9816 |